HIV infectious disease

Summary

HIV infectious disease (MONDO:0005109) is a disease (an umbrella term covering 5 Mondo subtypes) with 2 cohort genes (11 GWAS associations across 14 studies) and 6,481 clinical trials. Top therapeutic interventions include zidovudine, efavirenz, and abacavir.

At a glance

• Umbrella term: 5 Mondo subtypes
• Cohort genes: 2
• GWAS associations: 11
• Clinical trials: 6,481

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	HIV infectious disease
Mondo ID	MONDO:0005109
EFO	EFO:0000764
MeSH	D015658
DOID	DOID:526
ICD-10-CM	B20-B20
NCIT	C3108
SNOMED CT	86406008
UMLS	C0019693
MedGen	5583
Is cancer (heuristic)	no

Also known as: HIV infection · Human immunodeficiency virus caused disease or disorder · Human immunodeficiency virus disease or disorder · Human immunodeficiency virus infectious disease

Data availability: 11 GWAS associations (14 studies).

Disease family

An umbrella term covering 5 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › sexually transmitted disease › viral sexually transmitted disease › HIV infectious disease

Related subtypes (2): anogenital human papillomavirus infection, genital herpes

Subtypes (5): AIDS related complex, central nervous system AIDS arteritis, HIV wasting syndrome, AIDS, congenital human immunodeficiency virus

Genetics & variants

GWAS landscape

11 GWAS associations across 14 studies. Top hits map to 5 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs572880838	8e-09	AP3B1	G	6.71
rs185647096	3e-08	OSBPL2	?
rs2535307	4e-07	RNU6-1133P - C6orf15	C
rs11050931	7e-07	RNA5SP356 - IPO8	?
rs6076463	8e-07	PTPRA	T	0.17
kgp7815029	1e-06		?
rs6703307	2e-06	DPYD	?
rs7606492	2e-06	CYP1B1-AS1	?
kgp22385164	2e-06		G

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90481439	Verma A	2024	3,381	118,967	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481442	Verma A	2024	3,347	119,148	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481440	Verma A	2024	3,044	450,016	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481443	Verma A	2024	3,001	450,218	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481438	Verma A	2024	749	59,858	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90481441	Verma A	2024	737	59,917	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651616	Liu TY	2025	584	190,942	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90651602	Liu TY	2025	582	190,942	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST009417	Xie W	2017	556	0	Genome-Wide Analyses Reveal Gene Influence on HIV Disease Progression and HIV-1C Acquisition in Southern Africa.
GCST90473063	UK Biobank Whole-Genome Sequencing Consortium	2025	378	458,062	Whole-genome sequencing of 490,640 UK Biobank participants.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	2
Tier 3: regulatory	0
Tier 4: intronic/intergenic	7

MAF distribution

Bucket	Variants
common (>=0.05)	7
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	2

Functional consequences

Consequence	Count
intron_variant	4
5_prime_UTR_variant	2
unknown	2
intergenic_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs572880838	5	78294598	T>C,G	0.05	5_prime_UTR_variant	AP3B1	8e-09	Tier 2: splice/UTR
rs185647096	20	62254672	C>T		5_prime_UTR_variant	OSBPL2	3e-08	Tier 2: splice/UTR
rs2535307	6	31085964	C>A,G,T	0.48	intergenic_variant	RNU6-1133P - C6orf15	4e-07	Tier 4: intronic/intergenic
rs11050931	12	30506287	T>C,G	0.05	intron_variant	RNA5SP356 - IPO8	7e-07	Tier 4: intronic/intergenic
rs6076463	20	3032169	C>T	0.05	intron_variant	PTPRA	8e-07	Tier 4: intronic/intergenic
kgp7815029							1e-06	Tier 4: intronic/intergenic
rs6703307	1	97802581	A>C	0.05	intron_variant	DPYD	2e-06	Tier 4: intronic/intergenic
rs7606492	2	38204468	C>A,T	0.05	intron_variant	CYP1B1-AS1	2e-06	Tier 4: intronic/intergenic
kgp22385164				0.08			2e-06	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 0 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
CCNG1	HGNC:1592	ENSG00000113328	P51959	Cyclin-G1	gwas
HCG22	HGNC:27780	ENSG00000228789	E2RYF7	Protein PBMUCL2	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
CCNG1	Cyclin-G1	May play a role in growth regulation.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 2 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	2	1.8×	0.312

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
CCNG1	Other/Unknown	no		Cyclin_N, Cyclin-like_dom, Cyclin-like_sf
HCG22	Other/Unknown	no		EZH_Inhibitor

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
biceps brachii	1
corpus epididymis	1
jejunal mucosa	1
esophagus mucosa	1
lower esophagus mucosa	1
male germ line stem cell (sensu Vertebrata) in testis	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
CCNG1	292	ubiquitous	marker	jejunal mucosa, biceps brachii, corpus epididymis
HCG22	107	tissue_specific	yes	lower esophagus mucosa, male germ line stem cell (sensu Vertebrata) in testis, esophagus mucosa

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
CCNG1	2,603
HCG22	0

Structural data

PDB: 0 · AlphaFold-only: 2 · No structure: 0

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
CCNG1	P51959	85.69
HCG22	E2RYF7	69.41

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 7. Enrichment computed across 2 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Regulation of TP53 Expression and Degradation	1	519.1×	0.012	CCNG1
Regulation of TP53 Degradation	1	292.8×	0.012	CCNG1
Regulation of TP53 Activity	1	132.8×	0.018	CCNG1
Transcriptional Regulation by TP53	1	62.1×	0.028	CCNG1
RNA Polymerase II Transcription	1	22.5×	0.062	CCNG1
Gene expression (Transcription)	1	17.8×	0.065	CCNG1
Generic Transcription Pathway	1	15.1×	0.066	CCNG1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
regulation of cyclin-dependent protein serine/threonine kinase activity	1	732.7×	0.004	CCNG1
G1/S transition of mitotic cell cycle	1	200.6×	0.007	CCNG1
cell division	1	46.2×	0.022	CCNG1

Therapeutics

Drugs indicated for this disease

30 approved, 64 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Amprenavir	Approved (phase 4)
Azithromycin	Approved (phase 4)
Cabotegravir	Approved (phase 4)
Cobicistat	Approved (phase 4)
Darunavir	Approved (phase 4)
Didanosine	Approved (phase 4)
Doravirine	Approved (phase 4)
Efavirenz	Approved (phase 4)
Elvitegravir	Approved (phase 4)
Emtricitabine	Approved (phase 4)
Enfuvirtide	Approved (phase 4)
Epoetin Alfa	Approved (phase 4)
Etravirine	Approved (phase 4)
Fomivirsen	Approved (phase 4)
Fostemsavir	Approved (phase 4)
Ganciclovir	Approved (phase 4)
Ibalizumab	Approved (phase 4)
Isoniazid	Approved (phase 4)
Lamivudine	Approved (phase 4)
Lopinavir	Approved (phase 4)
Maraviroc	Approved (phase 4)
Nevirapine	Approved (phase 4)
Rifabutin	Approved (phase 4)
Rilpivirine	Approved (phase 4)
Ritonavir	Approved (phase 4)
Saquinavir	Approved (phase 4)
Somatropin	Approved (phase 4)
Stavudine	Approved (phase 4)
Tipranavir	Approved (phase 4)
Zidovudine	Approved (phase 4)
Abacavir	Phase 3 (in late-stage trials)
Acetaminophen	Phase 3 (in late-stage trials)
Acyclovir	Phase 3 (in late-stage trials)
Adefovir Dipivoxil	Phase 3 (in late-stage trials)
Albendazole	Phase 3 (in late-stage trials)
Albuvirtide	Phase 3 (in late-stage trials)
Aldesleukin	Phase 3 (in late-stage trials)
Apricitabine	Phase 3 (in late-stage trials)
Atazanavir	Phase 3 (in late-stage trials)
Atorvastatin	Phase 3 (in late-stage trials)
Bictegravir	Phase 3 (in late-stage trials)
Bleomycin	Phase 3 (in late-stage trials)
Buprenorphine	Phase 3 (in late-stage trials)
Cefixime	Phase 3 (in late-stage trials)
Cholecalciferol	Phase 3 (in late-stage trials)
Clotrimazole	Phase 3 (in late-stage trials)
Dapivirine	Phase 3 (in late-stage trials)
Dapsone	Phase 3 (in late-stage trials)
Dolutegravir	Phase 3 (in late-stage trials)
Erythromycin	Phase 3 (in late-stage trials)
Etoposide	Phase 3 (in late-stage trials)
Fluconazole	Phase 3 (in late-stage trials)
Fosamprenavir	Phase 3 (in late-stage trials)
Human Immunoglobulin G	Phase 3 (in late-stage trials)
Hydroxyurea	Phase 3 (in late-stage trials)
INTERFERON ALFA-2B	Phase 3 (in late-stage trials)
INTERFERON BETA-1B	Phase 3 (in late-stage trials)
Ibuprofen	Phase 3 (in late-stage trials)
Interferon Alfa	Phase 3 (in late-stage trials)
Lenacapavir	Phase 3 (in late-stage trials)
Levocarnitine	Phase 3 (in late-stage trials)
Methadone	Phase 3 (in late-stage trials)
Metoclopramide	Phase 3 (in late-stage trials)
Metronidazole	Phase 3 (in late-stage trials)
Miconazole	Phase 3 (in late-stage trials)
NONOXYNOL 9	Phase 3 (in late-stage trials)
Naltrexone	Phase 3 (in late-stage trials)
Nelfinavir	Phase 3 (in late-stage trials)
Nystatin	Phase 3 (in late-stage trials)
OMEGA-3-ACID ETHYL ESTERS	Phase 3 (in late-stage trials)
Ondansetron	Phase 3 (in late-stage trials)
PEGINTERFERON ALFA-2A	Phase 3 (in late-stage trials)
PEGINTERFERON ALFA-2B	Phase 3 (in late-stage trials)
Paclitaxel	Phase 3 (in late-stage trials)
Pioglitazone	Phase 3 (in late-stage trials)
Protease (Pancrelipase)	Phase 3 (in late-stage trials)
Pyrimethamine	Phase 3 (in late-stage trials)
Raltegravir	Phase 3 (in late-stage trials)
Ribavirin	Phase 3 (in late-stage trials)
Rosuvastatin	Phase 3 (in late-stage trials)
Semzuvolimab	Phase 3 (in late-stage trials)
Sulfadoxine	Phase 3 (in late-stage trials)
Sulfamethoxazole	Phase 3 (in late-stage trials)
Telaprevir	Phase 3 (in late-stage trials)
Tenofovir Alafenamide	Phase 3 (in late-stage trials)
Tenofovir Anhydrous	Phase 3 (in late-stage trials)
Tenofovir Disoproxil	Phase 3 (in late-stage trials)
Thymopentin	Phase 3 (in late-stage trials)
Trimethoprim	Phase 3 (in late-stage trials)
Valacyclovir	Phase 3 (in late-stage trials)
Vicriviroc	Phase 3 (in late-stage trials)
Vincristine	Phase 3 (in late-stage trials)
Zalcitabine	Phase 3 (in late-stage trials)
Zinc Ion	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Alendronic Acid, Aspirin, Baricitinib, Bcg Vaccine, Calcium Carbonate, Cannabidiol, Capsaicin, Carbamazepine, Cenicriviroc, Chloroquine, Clopidogrel, Cyanocobalamin, Cyclosporine, Cysteamine, Dasatinib Anhydrous, Delavirdine, Dextrose, Dronabinol, Envafolimab, Ergocalciferol, Estradiol, Etonogestrel, Etoricoxib, Fenofibrate, Filgrastim, Folic Acid, Gabapentin, Galantamine, Glycerin, Hepatitis B Virus Hbsag Surface Protein Antigen, Hepatitis B Virus Vaccine Inactivated, Hyaluronidase (Human Recombinant), Hydroxychloroquine, INTERFERON ALFA-2A, INTERFERON ALFA-N3, INTERFERON GAMMA-1B, Influenza Virus Vaccine, Islatravir, Isotretinoin, Lenalidomide, Leronlimab, Levonorgestrel, Lipoic Acid, Alpha, Losartan, Lovastatin, Lubiprostone, Medroxyprogesterone Acetate, Mifepristone, Miglustat, Minocycline, Mycophenolate Mofetil, Niacin, Norelgestromin, Obefazimod, Palifermin, Phenylbutanoic Acid, Prasterone, Prednisolone, Prednisone, Progesterone, Pyridostigmine, Pyridoxine, Rabies Vaccine, Regramostim, Rifapentine, Rifaximin, Romidepsin, Rosiglitazone, Ruxolitinib, Sargramostim, Sitagliptin, Sodium Chloride, Tamoxifen, Teduglutide, Telmisartan, Tetanus Toxoid, Thalidomide, Tremelimumab, Triptorelin, Tucidinostat, Valproic Acid, Vedolizumab, Vorinostat.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 2

Druggability breadth: 0 of 2 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
CCNG1	0	0
HCG22	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	CCNG1, HCG22

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
CCNG1	0	—
HCG22	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 6,481.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	577
PHASE3	467
PHASE2/PHASE3	56

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02656511	PHASE4	ACTIVE_NOT_RECRUITING	Immediate Initiation of Antiretroviral Therapy During Hyperacute HIV Infection
NCT03132311	PHASE4	RECRUITING	Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals
NCT03391921	PHASE4	ACTIVE_NOT_RECRUITING	Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study)
NCT04265950	PHASE4	ACTIVE_NOT_RECRUITING	Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial
NCT04270773	PHASE4	ACTIVE_NOT_RECRUITING	Immunogenicity and Safety of a 9-valent Human Papillomavirus Vaccine in HIV-positive Women
NCT04523519	PHASE4	RECRUITING	PrEP Intervention for People Who Inject Substances and Use Methamphetamine
NCT04616963	PHASE4	ACTIVE_NOT_RECRUITING	Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis
NCT04875819	PHASE4	RECRUITING	Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV
NCT05393193	PHASE4	ACTIVE_NOT_RECRUITING	POC HIV Testing and Early DTG Use for Infants
NCT05547048	PHASE4	RECRUITING	Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
NCT05630638	PHASE4	RECRUITING	Doravirine Dose Optimisation in Pregnancy
NCT05663892	PHASE4	ACTIVE_NOT_RECRUITING	Drug-Drug Interaction Study in Trans Women Living With HIV
NCT05669534	PHASE4	RECRUITING	Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
NCT05694637	PHASE4	ENROLLING_BY_INVITATION	Botswana Smoking and Abstinence Reinforcement Trial
NCT06037564	PHASE4	ENROLLING_BY_INVITATION	B-free Multistage Trial
NCT06374758	PHASE4	RECRUITING	Accelerated ART Initiation for PWHIV Who Are Out of Care
NCT06375304	PHASE4	NOT_YET_RECRUITING	The Antiretroviral Speed Access Program Switch (ASAP-Switch) Study
NCT06436274	PHASE4	ACTIVE_NOT_RECRUITING	Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.
NCT06438146	PHASE4	RECRUITING	LIROH - Liraglutide for Obesity in HIV
NCT06474364	PHASE4	RECRUITING	HIV Prevention and Care Interventions for Youth in Uganda
NCT06514547	PHASE4	RECRUITING	Vaccine Immunity and Inflammation in the Aging Person Living With HIV
NCT06526507	PHASE4	ENROLLING_BY_INVITATION	PrEPARE-SCALE: Scaling up Integrated PrEP Delivery in Kenyan Maternal and Child Health Clinics
NCT06602622	PHASE4	RECRUITING	Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI
NCT06787976	PHASE4	NOT_YET_RECRUITING	Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.
NCT06829238	PHASE4	RECRUITING	Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
NCT06830668	PHASE4	NOT_YET_RECRUITING	Same-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation
NCT06854029	PHASE4	NOT_YET_RECRUITING	NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings
NCT06856174	PHASE4	RECRUITING	Menopausal HT for Women Living With HIV (HoT)
NCT06907056	PHASE4	RECRUITING	Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in Mexico
NCT06908252	PHASE4	RECRUITING	MAPS PrEP Van Study
NCT06967519	PHASE4	RECRUITING	OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa
NCT06967753	PHASE4	RECRUITING	Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)
NCT07000513	PHASE4	NOT_YET_RECRUITING	HIV Self-Testing and Long-Acting Injectables for HIV Treatment and Prevention Among Commercial Minibus Drivers (I-TEST LAIs) in Nigeria
NCT07006246	PHASE4	ACTIVE_NOT_RECRUITING	Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa
NCT07031063	PHASE4	RECRUITING	Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience
NCT07076043	PHASE4	RECRUITING	Multi-product PrEP Delivery to Young Women Seeking Reproductive Health Services and Coverage of HIV Prevention
NCT07110831	PHASE4	NOT_YET_RECRUITING	Disposition Kinetics of Dolutegravir Among People Living With HIV With Major Depression in Nigeria
NCT07138144	PHASE4	RECRUITING	Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up
NCT07199335	PHASE4	RECRUITING	Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs
NCT07210125	PHASE4	ACTIVE_NOT_RECRUITING	Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ZIDOVUDINE	4	85
EFAVIRENZ	4	84
ABACAVIR	4	75
TENOFOVIR DISOPROXIL	4	72
DARUNAVIR	4	69
RITONAVIR	4	67
LOPINAVIR	4	59
EMTRICITABINE	4	57
RALTEGRAVIR	4	52
ATAZANAVIR	4	50
LAMIVUDINE	4	49
NEVIRAPINE	4	45
STAVUDINE	4	38
DIDANOSINE	4	26
MARAVIROC	4	25
LEUCOVORIN	4	21
FOSCARNET	4	20
SAQUINAVIR	4	19
ENFUVIRTIDE	4	18
NELFINAVIR MESYLATE	4	18
INDINAVIR SULFATE	4	15
DOLUTEGRAVIR	4	14
ETRAVIRINE	4	11
FOSAMPRENAVIR	4	11
ACYCLOVIR	4	10
VALACYCLOVIR	4	10
ISONIAZID	4	9
FLUCONAZOLE	4	8
GANCICLOVIR	4	8
RIFABUTIN	4	8